Ancell

anti-CD272 [BTLA] (human), mAb (ANC6E9) (APC)

CHF 551.00

In stock

ANC-272-060120 testsCHF 551.00

More Information
Product Details
Synonyms	BTLA; B- and T-lymphocyte Attenuator
Product Type	Monoclonal Antibody
Properties
Clone	ANC6E9
Isotype	Mouse IgG1κ
Immunogen/Antigen	Recombinant soluble human CD272.
Label/Conjugates	APC
Application	ELISA Flow Cytometry Functional Application
Crossreactivity	Human
Purity	≥95% (SDS-PAGE)
Formulation	50mM Sodium Phosphate pH 7.5, 500mM Potassium Chloride, 150mM NaCl, 15% Glycerol, 0.2% BSA, 0.04% NaN3 (as a preservative).
Isotype Negative Control	Mouse IgG1 Isotype Control (APC)
Other Product Data	Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet.
Declaration	Manufactured by Ancell Corporation.
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	+4°C
Handling Advice	Do not freeze. Protect from light.
Use/Stability	Stable for at least 1 year after receipt when stored at +4°C.
Documents
MSDS	Inquire
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Human CD272 (BTLA; B and T Lymphocyte Attenuator) is a member of the immunoglobulin superfamily and has sequence homology to PD-1 and CTLA-4. It is expressed on T and B lymphocytes and other hemopoetic lineages. Engagement of this molecule by its ligand CD270 (HVEM) can downregulate activated T and B cell responses. CD272 levels on antigen specific CD8+ T cells have been reported to decrease in viral specific, but not melanoma specific activated lines. Polymorphism of the CD272 molecule has been linked to rheumatoid arthritis.

Call	+41 61 926 6040
Fax	+41 61 926 6049